(Duvakitug)Biosimilar Reference Antibody-GS40200

货号：GS40200

Duvakitug (TEV-48574) is an investigational humanized monoclonal antibody being developed by Teva and Sanofi for the treatment of moderate-to-severe Crohn's disease (CD) and ulcerative colitis (UC), the two major forms of Inflammatory Bowel Disease (IBD). It functions as a targeted biologic that inhibits a key inflammatory driver, the TL1A protein (also known as TNF-like ligand 1A or TNFSF15). Duvakitug has demonstrated strong efficacy and safety in Phase 2b clinical trials, positioning it as a promising next-generation therapy with the potential to transform IBD care. It is currently advancing into Phase 3 development.